Ocugen to Share Gene Therapy Advances at May Conferences: What It Means for the IRD Community
For individuals and families navigating the challenges of inherited retinal diseases (IRDs), news of advancements in gene therapy offers a beacon of hope. Ocugen, a biotechnology company focused on gene therapies for blindness, recently announced its participation in key scientific and investor conferences in May 2026. These presentations highlight the company's commitment to developing innovative treatments for IRDs and other blinding diseases, which is a significant development for our community.
Ocugen is set to present on its modifier gene therapy platform at two important events: the Retina World Congress and the Stifel 2026 Virtual Ophthalmology Forum. The Retina World Congress included an